Role of allogeneic stem cell transplantation in mantle cell lymphoma

• Type of Material: Article
• Authors: Jonathon Cohen, Emory University; Linda J. Burns, University of Minnesota; Veronika Bachanova, University of Minnesota
• Language: English
• Date: 2015-04
• Publisher: Wiley: 12 months
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: Copyright John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
• Final Published Version (URL): http://dx.doi.org/10.1111/ejh.12442
• Title of Journal or Parent Work: European Journal of Haematology
• ISSN: 0902-4441
• Volume: 94
• Issue: 4
• Start Page: 290
• End Page: 297
• Keywords: review; BONE-MARROW-TRANSPLANTATION; BLOOD; PHASE-II; allogeneic donor; NON-HODGKINS-LYMPHOMA; PLUS RITUXIMAB; EUROPEAN GROUP; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; Hematology; INTERNATIONAL PROGNOSTIC INDEX; REDUCED-INTENSITY; Life Sciences & Biomedicine; PROGRESSION-FREE SURVIVAL; Science & Technology; hematopoetic cell transplantation; mantle cell lymphoma
• Research Categories: Health Sciences, Oncology; Health Sciences, Immunology

Abstract

Despite a wide spectrum of treatment options, mantle cell lymphoma (MCL) remains a challenging hematologic malignancy to manage. Advances in front-line therapy, including the monoclonal antibody rituximab and increasing use of cytarabine, have improved remission rates. Autologous hematopoietic cell transplantation (HCT) can effectively consolidate remission of MCL, leading to encouraging survival beyond 5 yr. However, nearly all patients with MCL will relapse and require salvage therapy. Novel agents such as ibrutinib, bortezomib, and lenalidomide have dramatically expanded the options for treating relapsed MCL. In this review, we summarize the clinical evidence supporting the use of allogeneic donor HCT in MCL and make recommendations on indications for its use. Data suggest that allogeneic donor HCT is the only curative therapy for patients with poor prognosis or aggressive MCL. Patient selection, timing, and optimal use remain a matter of scientific debate and given the rapidly changing therapeutic landscape of MCL, the outcomes of allogeneic HCT should be interpreted in the context of novel therapeutics.